Free Trial

MDxHealth Q2 2023 Earnings Report

MDxHealth logo
$2.00 +0.02 (+0.75%)
As of 12:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MDxHealth EPS Results

Actual EPS
-$3.00
Consensus EPS
-$3.20
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A

MDxHealth Revenue Results

Actual Revenue
$16.75 million
Expected Revenue
$15.14 million
Beat/Miss
Beat by +$1.61 million
YoY Revenue Growth
N/A

MDxHealth Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

MDxHealth Earnings Headlines

Piper Sandler Sticks to Its Buy Rating for MDxHealth (MDXH)
MDxHealth sees FY25 revenue $108M-$110M, consensus $98.93M
Did You See Trump’s Manhattan Project Bombshell?
This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)... Trump’s first Executive Order would easily be the boldest, most mind-blowing and daring American initiative ANY U.S. President has launched in over 80 years.
See More MDxHealth Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MDxHealth? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MDxHealth and other key companies, straight to your email.

About MDxHealth

MDxHealth (NASDAQ:MDXH), a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

View MDxHealth Profile

More Earnings Resources from MarketBeat